KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBITDA (2023 - 2025)

Biocryst Pharmaceuticals' EBITDA history spans 9 years, with the latest figure at $244.7 million for Q4 2025.

  • For Q4 2025, EBITDA rose 968.9% year-over-year to $244.7 million; the TTM value through Dec 2025 reached $263.0 million, up 394.5%, while the annual FY2025 figure was $263.0 million, 394.5% up from the prior year.
  • EBITDA reached $244.7 million in Q4 2025 per BCRX's latest filing, up from $12.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $244.7 million in Q4 2025 to a low of -$200.5 million in Q4 2023.
  • Average EBITDA over 3 years is -$3.0 million, with a median of -$12.3 million recorded in 2024.
  • Peak YoY movement for EBITDA: skyrocketed 85.95% in 2024, then surged 968.9% in 2025.
  • A 3-year view of EBITDA shows it stood at -$200.5 million in 2023, then soared by 85.95% to -$28.2 million in 2024, then soared by 968.9% to $244.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EBITDA are $244.7 million (Q4 2025), $12.4 million (Q3 2025), and $5.6 million (Q2 2025).